Table 2 CAR-T treatment history prior to loncastuximab treatment.
Loncastuximab line of therapy | ||
|---|---|---|
3rd Line N = 95 (%) | 4th Line N = 23 (%) | |
2nd Line CAR-T | ||
CAR-T product | ||
Axicabtagene ciloleucel | 62 (65%) | – |
Lisocabtagene maraleucel | 33 (35%) | – |
Best response to 2nd line CAR-T | ||
Complete response | 23 (24%) | – |
Partial response | 44 (46%) | – |
Stable disease | 11 (12%) | – |
Progressive disease | 16 (17%) | – |
Unknown | 1 (1%) | – |
3rd Line CAR-T | ||
CAR-T product | ||
Axicabtagene ciloleucel | – | 18 (78%) |
Tisagenlecleucel | – | 5 (22%) |
Best response to 3rd line CAR-T | ||
Complete response | – | 12 (52%) |
Partial response | – | 5 (22%) |
Stable disease | – | 4 (17%) |
Progressive disease | – | 2 (9%) |
Refractory to CAR-T | ||
No. with response status | 94a | 23 |
CAR-T responders | 67 (71%) | 17 (74%) |
Refractory to CAR-T | 27 (29%) | 6 (26%) |
Bridging therapy to CAR-T | ||
Yes | 12 (13%) | 13 (57%) |
No | 78 (82%) | 7 (30%) |
Unknown | 5 (5%) | 3 (13%) |
Time from CAR-T infusion to progression, days | ||
No. with recorded dates | 55 | 8 |
Mean (SD) | 135.7 (113.3) | 198.9 (98.2) |
Median (Q1, Q3) | 123.0 (42.0, 198.0) | 221.5 (150.8, 254.5) |
Time from CAR-T infusion to loncastuximab initiation, days | ||
No. with recorded dates | 75 | 9 |
Mean (SD) | 205.7 (147.8) | 266.0 (109.4) |
Median (Q1, Q3) | 203.0 (92.0, 280.0) | 297.0 (215.5, 358.0) |
